Four insights:
1. PSPC will offer Kalypso’s ketamine treatments to patients suffering from acute and chronic pain.
2. Kalypso was established by two anesthesiologists and two pain management specialists in 2016 and provides ketamine treatments for patients suffering from chronic pain, neuropathic pain, anxiety and fibromyalgia among other conditions.
3. Ninety percent of Kalypso patients see positive treatment results compared to national averages of between 60 percent and 70 percent, according to Ryan Bridges, COO at Kalypso.
4. Patents on the technology are pending.
More articles on practice management:
Johnson & Johnson, Stryker & more: How 8 companies are performing in spine
DJO, SeaSpine & more: 4 device company launches, releases
7 key updates on Globus Medical in 2019
